American Psychiatric Association: Diagnostic, Statistical Manual of Mental Disorders, 4th(DSM-IV)Washington, DC: American Psychiatric Association, 1994.
2.
BangsME, JinL, ZhangS, DesaiahD, AllenAJ, ReadHA, RegevA, WernickeJF. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf, 31:345–354. 2008.
3.
CaballeroJ, NahataMC. Atomoxetine hydrochloride for the treatment of attention deficit/hyperactivity disorder. Clin Ther, 25:3065–3083. 2003.
4.
Cope-YokoyamaS, FinegoldMJ, SturnioloGC, KimK, MescoliC, RuggeM, MediciV. Wilson disease: Histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol, 16:1487–1494. 2010.
5.
HussainiSH, FarringtonEA. Idiosyncratic drug-induced liver injury: An overview. Expert Opin Drug Saf, 6:673–684. 2007.
6.
KormanJD, VolenbergI, BalkoJ, WebsterJ, SchiodtFV, SquiresRHJr., FontanaRJ, LeeWM, SchilskyML. Pediatric and Adult Acute Liver Failure Study Groups. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology, 48:1167–1174. 2008.
7.
LewisJH. Drug-induced liver disease. Med Clin North Am, 84:1275–1311. 2000.
8.
LimJR, FaughtPR, ChalasaniNP, MollestonJP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr, 148:831–834. 2006.
9.
PliszkaS. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 46:894–921. 2007.
StojanovskiSD, CasavantMJ, MousaHM, BakerP, NahataMC. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila), 45:51–55. 2007.
12.
VisserSN, LesesneCA, PerouR. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics119 Suppl1:99–106. 2007.
